For research use only. Not for therapeutic Use.
Berubicin (Cat No.: I040080) is a potent anthracycline chemotherapeutic agent designed to cross the blood-brain barrier (BBB), making it a promising candidate for glioblastoma and other brain tumor treatments. Unlike traditional anthracyclines, it effectively targets CNS malignancies by inhibiting topoisomerase II, leading to DNA damage and apoptosis in cancer cells. With strong anti-tumor activity and improved CNS penetration, Berubicin is under investigation for neuro-oncology drug development, offering potential advancements in brain cancer therapy and precision medicine for difficult-to-treat tumors.
| CAS Number | 677017-23-1 |
| Synonyms | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-phenylmethoxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione |
| Molecular Formula | C34H35NO11 |
| Purity | ≥95% |
| InChI | InChI=1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1 |
| InChIKey | FIGNGSHKNAHTSH-JJMFXPFOSA-N |
| SMILES | CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6 |
| Reference | [1]. Kazerooni R, et al. Phase I clinical pharmacokinetics of RTA 744 (berubicin (B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol)[J]. Molecular Cancer Therapeutics, 2007, 6(11_Supplement): B101-B101. |
